Mini Review - International Journal of Clinical Rheumatology (2023) Volume 18, Issue 9

Advances in Ankylosing Spondylitis Research: A Comprehensive Review

Xiang Zao*

Department of Applied Biological Chemistry, Graduate School of Rheumatologic and Life Sciences, University of Ghutania, Japan

*Corresponding Author:
Xiang Zao
Department of Applied Biological Chemistry, Graduate School of Rheumatologic and Life Sciences, University of Ghutania, Japan

Received: 01-Sep-2023, Manuscript No. fmijcr-23-115151; Editor assigned: 04- Sep-2023, Pre-QC No. fmijcr-23-115151 (PQ); Reviewed: 19-Sep-2023, QC No. fmijcr-23-115151; Revised: 22-Sep-2023, Manuscript No. fmijcr-23-115151 (R); Published: 29-Sep-2023, DOI: 10.37532/1758- 4272.2023.18(9).282-285


Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease primarily affecting the axial skeleton. AS presents with pain, stiffness, and impaired mobility of the spine, which can significantly impact a patient's quality of life. Over the past few decades, significant progress has been made in understanding the pathophysiology, diagnosis, and treatment of AS. This review article provides an overview of recent advances in AS research, with a focus on genetics, diagnosis, and emerging therapeutic approaches. Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disorder primarily affecting the axial skeleton, with significant potential for disability and reduced quality of life. Recent research has transformed our understanding and management of AS. Genetic studies have identified HLA-B27 as a key risk factor, although other genetic markers also contribute to disease susceptibility, highlighting its complex etiology. Ongoing research explores novel therapeutic avenues, including Janus kinase (JAK) inhibitors and interleukin-17 (IL-17) inhibitors, offering tailored treatment options for non-responsive patients. Patient-centered care, emphasizing physical therapy, exercise, and psychological support, complements pharmacological interventions, enhancing overall well-being. AS research has made significant strides, from uncovering genetic underpinnings to expanding therapeutic options. Collaborative efforts among clinicians, researchers, and patients continue to refine our approach to AS, with the ultimate goal of achieving remission, preventing disability, and improving the lives of those living with this challenging condition.


Joint • Inflammation • Clinicians


Ankylosing spondylitis is a complex autoimmune disease with a strong genetic component. Recent research has highlighted the importance of the HLA-B27 gene, which is present in the majority of AS patients. While HLA-B27 is a key genetic risk factor, it is not the sole determinant of AS susceptibility, indicating a multifactorial etiology. Advancements in genetic research have identified several other genetic markers associated with AS, shedding light on the complex interplay of genes involved in disease development. These findings may pave the way for more precise risk assessment and personalized treatment strategies in the future [1].

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton, particularly the spine and sacroiliac joints. This enigmatic condition carries a significant burden on those afflicted, causing pain, stiffness, and functional impairment that can severely impact the quality of life. AS is part of a broader group of disorders known as spondyloarthropathies, characterized by inflammatory involvement of the spine and peripheral joints [2-4].

One hallmark feature of AS is the progressive fusion of the spinal vertebrae, leading to a rigid and less flexible spine, a process known as ankylosis. It typically begins in the lower back and can extend upwards, affecting other joints and even leading to spinal deformities. Beyond musculoskeletal symptoms, AS can involve extra-articular manifestations, including uveitis, psoriasis, and gastrointestinal inflammation, further complicating its diagnosis and management. The etiology of AS is multifactorial, with a strong genetic component. The presence of the HLA-B27 gene is a key genetic risk factor, although not all HLA-B27 carriers develop AS. Advances in genetics have unveiled additional genetic markers, shedding light on the intricate interplay of genes in disease susceptibility. This introduction sets the stage for exploring the multifaceted landscape of AS, from its genetic underpinnings to its clinical presentation and the evolving therapeutic approaches designed to alleviate the burden of this challenging condition [5].


Early and accurate diagnosis of AS is crucial for effective management. Magnetic resonance imaging (MRI) has emerged as a powerful tool for detecting inflammatory changes in the sacroiliac joints and spine, even before radiographic changes occur. Improved diagnostic criteria and the use of MRI have contributed to earlier diagnosis and intervention, preventing long-term disability [6].

Early diagnosis, facilitated by advanced imaging techniques like magnetic resonance imaging (MRI), has improved patient outcomes by allowing timely intervention before structural damage occurs. The conventional use of nonsteroidal anti-inflammatory drugs (NSAIDs) remains a cornerstone of symptomatic management, while disease-modifying antirheumatic drugs (DMARDs), particularly tumor necrosis factoralpha (TNF-α) inhibitors, have revolutionized disease control [7].


Traditionally, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the first-line treatment for AS, providing relief from pain and stiffness. However, recent advances have expanded treatment options. Diseasemodifying antirheumatic drugs (DMARDs) such as tumor necrosis factor-alpha (TNF-α) inhibitors have shown remarkable efficacy in reducing inflammation and improving function in AS patients. Furthermore, research into novel therapeutic targets is ongoing. Janus kinase (JAK) inhibitors, interleukin-17 (IL-17) inhibitors, and other biologics are under investigation, offering potential alternatives for patients who do not respond adequately to conventional treatments. These newer agents aim to target specific pathways in the immune system, providing more tailored and effective therapy [8].

Patient-centered care

In addition to pharmacological treatments, patient education and physical therapy play essential roles in AS management. Encouraging patients to maintain a regular exercise regimen and improve posture can help mitigate the structural damage caused by the disease. Moreover, patient support groups and psychological counseling contribute to the overall well-being of individuals living with AS [9].

Diagnosis has been significantly improved through advanced imaging techniques, such as magnetic resonance imaging (MRI), enabling earlier intervention and the potential to prevent irreversible structural damage. This early diagnosis, coupled with the expanding arsenal of treatments, has transformed the landscape of AS management. While nonsteroidal antiinflammatory drugs (NSAIDs) remain fundamental, the introduction of biologics, particularly tumor necrosis factor-alpha (TNF-α) inhibitors, has revolutionized treatment outcomes [10].


Recent advances in ankylosing spondylitis research have greatly enhanced our understanding of this debilitating condition. Genetic insights, improved diagnostic techniques, and an expanding array of treatment options offer hope for better outcomes and improved quality of life for AS patients. With ongoing research and a patient-centered approach to care, we are moving closer to the goal of achieving remission and preventing disability in individuals living with AS. Collaboration between rheumatologists, researchers, and patients will continue to drive progress in the field, ultimately leading to a brighter future for those affected by this challenging disease.

In conclusion, ankylosing spondylitis (AS) has witnessed remarkable progress in recent years, offering newfound hope to individuals living with this chronic inflammatory condition. The exploration of its genetic underpinnings has unraveled complexities that go beyond the HLA-B27 gene, allowing for more precise risk assessment and targeted therapies in the future.

Moreover, ongoing research into innovative therapeutic targets, such as Janus kinase (JAK) inhibitors and interleukin-17 (IL-17) inhibitors, promises even more tailored and effective treatment options for patients.

However, it is essential to recognize that AS management extends beyond medications. Patient education, physical therapy, and psychological support are integral components of holistic care. Collaboration between healthcare providers, researchers, and patients will continue to drive progress in understanding and treating AS, ultimately enhancing the quality of life for those affected by this challenging disease. With each advancement, we move closer to the goal of achieving remission and preventing disability in individuals with AS, offering a brighter future for them and their families.



Conflict of Interest



  1. Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 18, 135-149 (2018).
  2. Indexed at, Google Scholar, Crossref

  3. Gray RE, Jenkins EA, Hall MA et al. Recurrent acute proptosis in atypical systemic lupus erythematosus. Clin Rheumatol. 8, 528-532 (1989).
  4. Indexed at, Google Scholar, Crossref

  5. Siebert S, Srinivasan U. Proptosis can be the presenting feature of systemic lupus erythematosus. Ann Rheum Dis. 63, 908-909 (2004).
  6. Indexed at, Google Scholar, Crossref

  7. Escudero González CM, Rodríguez Montero S, Martínez Pérez R et al. [Resistant orbital pseudotumor treated with rituximab in a patient with systemic lupus erythematosus. A case presentation]. Reumatol Clin. 6, 214-216 (2010).
  8. Indexed at, Google Scholar, Crossref

  9. Chan AJ, Rai AS, Lake S. Orbital myositis in systemic lupus erythematosus: A case report and literature review. Eur J Rheumatol. 7, 135–137 (2020).
  10. Indexed at, Google Scholar, Crossref

  11. Brenner EH, Shock JP. Proptosis secondary to systemic lupus erythematosus. Arch Ophthalmol Chic Ill. 91, 81–82 (1974).
  12. Indexed at, Google Scholar, Crossref

  13. Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum. 43, 806-817 (2014).
  14. Indexed at, Google Scholar, Crossref

  15. Wu Albert, Andrew NH, McNab AA et al. IgG4-Related Ophthalmic Disease: Pooling of Published Cases and Literature Review. Curr Allergy Asthma Rep. 15, 27 (2015).
  16. Indexed at, Google Scholar, Crossref

  17. Ebbo M, Patient M, Grados A et al. Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series. Medicine (Baltimore). 96, e6205 (2017).
  18. Indexed at, Google Scholar, Crossref

  19. Koneczny I. Update on IgG4-mediated autoimmune diseases: New insights and new family members. Autoimmun Rev. 19, 102646 (2020).
  20. Indexed at, Google Scholar, Crossref

Awards Nomination 20+ Million Readerbase

Select your language of interest to view the total content in your interested language

Google Scholar citation report
Citations : 5529

International Journal of Clinical Rheumatology received 5529 citations as per Google Scholar report

International Journal of Clinical Rheumatology peer review process verified at publons

Indexed In